Citations

Clear

87 citation(s) found for "Schmitz, KH".

Colony‐stimulating factor 1 receptor‐related disorder: Clinical variability of biallelic variants
Milanowski, Łukasz , Santos, Mara Lucia Schmitz Ferreira , Teive, Helio G., Fink, John K., Orthmann‐Murphy, Jennifer, Arnold, Kaley, Wszołek, Zbigniew K. , Wszolek, Z.K. , Milanowski, Łukasz M , Souza, Josiane , Teive, Hélio Afonso Ghizoni , Fink, John K. , Orthmann‐Murphy, Jennifer , Dulski, Jarosław , Group, CSF1R‐RD Study

Mayo Clinic

Developmental Medicine & Child Neurology | September 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/dmcn.70515 | PMID 42706750 Get It

Abstract Biallelic colony‐stimulating factor 1 receptor ( CSF1R ) variants are a major cause of early‐onset CSF1R ‐related disorder (CSF1R‐RD), although fewer than 30 cases have been reported and genotype–phenotype correlations remain unclear. The aim of this study was to characterize the clinical, radiological, and genetic features of patients with brain abnormalities, neurodegeneration, and dysosteosclerosis (BANDDOS). Six patients with biallelic CSF1R variants underwent detailed clinical, neurological, and magnetic resonance imaging evaluation. Three siblings with a homozygous p.Gly585Val variant showed marked phenotypic variability, ranging from severe childhood‐onset neurodegeneration to an asymptomatic presentation, all with white matter abnormalities. Three unrelated patients carried different biallelic CSF1R variants and presented with congenital skeletal abnormalities or early‐onset neurological disease of variable severity. These cases broaden the phenotypic spectrum of biallelic CSF1R‐RD and demonstrate that disease severity cannot be predicted solely by genotype, suggesting an important role for genetic or environmental modifiers.
Pathogenic MAPK8IP3 variants drive distinct motor and behavioral phenotypes in humans and mice
Watkins, Lyndsay R. , Geltzeiler, Alexa, Patel, Priya, Ortiz-Perez, Judit, Schmidt, Danielle, Schmitz, C, Aguilar, Jalen, Ghanta, Shraddha, Chung, Wendy. K., Gowrishankar, Swetha , Lambert, Laura, Crowder, Camerron M. , Geltzeiler, Alexa , Ortiz, Judit Perez, Chung, Wendy K.

Mayo Clinic

No container title available | July 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.07.20.739682 Get It

ABSTRACT Pathogenic variants in MAPK8IP3 (JIP3) cause Neurodevelopmental Disorder with or without variable Brain Abnormalities (NEDBA), characterized by cognitive impairment, global developmental delay, motor dysfunction, abnormal muscle tone, behavioral dysregulation including autism and attention deficit hyperactivity disorder (ADHD), seizures, and structural brain abnormalities. While more than 30 largely de novo MAPK8IP3 variants have been reported, the functional impact of variants across JIP3 protein structural domains is poorly defined. To address this knowledge gap, we compare clinical features of individuals with a truncating (p.E27X) or one of two missense (p.R578C and p.R1146C) variants from distinct JIP3 functional protein domains to corresponding knock-in mouse models. Our findings showed that all individuals, regardless of variant type, exhibited delays in language and gross motor function, but individual variants were associated with distinct motor, cognitive, and psychiatric symptoms. Corresponding homozygous p.E27X and p.R1147C variant mice resulted in embryonic lethality, consistent with essential roles for JIP3 in early neurodevelopment. Behavioral characterization of viable heterozygous mice revealed variant-specific locomotor, motor coordination, and hindlimb clasping defects that closely recapitulate clinical observations. Heterozygous p.R579C mice exhibited reduced locomotion, impaired motor performance, and hypertonia-like clasping, mirroring human motor deficits. In contrast, p.R1147C mice displayed hyperactivity, hindlimb clasping, and decreased brain weight, paralleling human clinical features. Together, our findings demonstrate that while distinct MAPK8IP3 variants lead to some shared phenotypes, they are also associated with distinct phenotypes that could reveal domain-specific aspects of JIP3 function. This work establishes the first domain-resolved in vivo rodent models of NEDBA and provides a validated translational platform for mechanistic investigation and preclinical therapeutic testing.
The Problem of Preservation in the 1990s: II. Formaldehyde and Formaldehyde-Releasing Biocides: Incidences of Cross-Reactivity and the Significance of the Positive Response to Formaldehyde
Fransway, Anthony F., Schmitz, Norma A.

Mayo Clinic

American Journal of Contact Dermatitis | April 16, 2026 | Volume: 2 | Issue: 2 | Pages: 78-88

10.1053/ajcd.1991.2301 Get It

Exercise recommendations for older adults living with and beyond cancer: A consensus statement by the Advancing Capacity to Integrate Exercise Into the Care of Older Cancer Survivors expert panel
Winters‐Stone, Kerri M. , Meyers, G., Cheville, Andrea , Garcia, José M. , Mohile, Supriya G. , Mustian, Karen, Neil‐Sztramko, Sarah, Schwartz, Anna L. , Sitemba, Jessica, Smith, Robert, Campbell, K., Mustian, Karen M. , Neil‐Sztramko, Sarah , Cheville, Andrea L , McNeely, Margaret L , Neil-Sztramko, Sarah , Schmitz, Kathryn H , Campbell, Kristin L , Winters-Stone, Kerri M , Garcia, Jose M , Eckstrom, Elizabeth , Rogers, Laura Q. , Schmitz, Kathryn H.

Mayo Clinic

Cancer | January 7, 2026 | Volume: 132 | Issue: 2 | Pages: No page available

10.1002/cncr.70252 | PMID 41499155 Get It

Abstract Background The number of cancer survivors aged older than 65 years is rising rapidly. Current evidence‐based exercise guidelines lack specific guidance for older cancer survivors as a result of insufficient evidence. An expert panel was convened to develop consensus‐based recommendations for exercise in older cancer survivors. Methods The development of recommendations was guided by the Grading of Recommendations Assessment, Development, and Evaluation Evidence‐to‐Decision framework for good practice statements. The panel drew from the available literature, a Delphi survey of exercise and health professionals, other exercise guidelines, clinical and research expertise, and interest‐holder input provided by a community advisory board of older cancer survivors and caregivers ( n = 11). Recommendations had to be deemed accessible (i.e., no added barriers) to older cancer survivors and feasible to implement. The panel voted on the strength of the recommendation for or against each statement, with consensus set at 85% agreement. Results Consensus was reached on 11 recommendations covering the following areas: medical evaluation/clearance for exercise, pre‐exercise assessment, exercise prescription, exercise tolerance and safety, exercise delivery, and behavioral support. The recommendations aimed to promote engagement in and uptake of appropriately prescribed exercise programming by older cancer survivors, while keeping barriers and risks as low as possible. Conclusions Older cancer survivors can benefit from appropriately prescribed exercise, which should be an essential component of their cancer care. Exercise and health professionals need to consider the unique needs of older cancer survivors to ensure that exercise is safe and effective for this population, while also reducing barriers to reach as many people as possible.
Abstract 4369439: Concurrent Quadruple Valve Replacement and Patent Foramen Ovale Closure for Carcinoid Heart Disease
Schmitz, Katlin , Elhadi, Muhammed

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4369439 Get It

Introduction: Carcinoid cancer is a rare neuroendocrine tumor (NET) secreting vasoactive substances. Case Presentation: A 66-year-old woman presented to cardiology clinic for evaluation of dyspnea with exertion and leg swelling. Comorbidities included chronic kidney disease and a history of jejunal neuroendocrine tumor (NET) with prior resection and recent recurrence complicated by peritoneal carcinomatosis. A transthoracic echocardiogram was obtained at time of recurrence (1 year prior to presentation) and showed mild mitral regurgitation (MR), mild bi-atrial enlargement, moderate tricuspid regurgitation (TR), and mild aortic regurgitation (AR) with preserved ejection fraction. In clinic, physical exam showed jugular venous distention with prominent V waves and a systolic and diastolic murmur. Transthoracic echocardiogram (TTE) demonstrated severe TR, moderate to severe AR, moderate MR, severe pulmonary valve regurgitation, and a right to left shunt with enlarged right ventricle and reduced function. Patient was diagnosed with left and right carcinoid heart disease involving all 4 cardiac valves in the setting of a patent foramen ovale (PFO). After multidisciplinary discussion, surgical intervention was recommended. She underwent successful cardiopulmonary bypass with mitral valve replacement, aortic valve, pulmonary valve replacement, and tricuspid valve replacement in addition to closure of PFO. She did well postoperatively and was stable for dismissal from the hospital after 12 days. Discussion: Rarely, carcinoid heart disease can involve the left side of the heart. Left sided involvement is typically seen in the presence of a right to left side cardiac shunt. In patients with severe valve dysfunction secondary to carcinoid heart syndrome, surgical intervention is the definitive treatment and has been found to improve quality of life and prolong survival
Abstract 4370783: Kounis Syndrome: A Rare but Noteworthy Cause of Acute Coronary Syndrome
Nouraee, Cyrus , Schmitz, Katlin, Mankad, Sunil , Schmitz, Katlin

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4370783 Get It

Kounis syndrome (KS) is a dangerous and rare acute coronary syndrome elicited in the setting of an allergic, hypersensitivity, or anaphylactic reaction. The syndrome is caused by mast cell activation leading to a release of proinflammatory mediators that can promote coronary vasospasm, atheromatous plaque erosion with rupture, or both. We present the case of a 48-year-old female with a past medical history of type 2 diabetes, hypertension, and chronic kidney disease stage 3 who presented via ambulance with anaphylaxis following an unknown allergen exposure. She was immediately given intramuscular epinephrine with resolution of symptoms, but she continued to have chest discomfort with radiation to her back. Initial EKG showed deep ST depressions in numerous leads (mainly the inferior and anterolateral leads) with ST elevations in leads V1 and aVR, consistent with diffuse subendocardial ischemia (Figure 1). Initial troponin was 2,122 which peaked at 5,328. Coronary angiogram was immediately obtained which showed patent coronary arteries with minimal narrowing of the distal left anterior descending artery. Because of this, cardiac MRI was obtained which showed subendocardial delayed enhancement at the basal and mid left ventricle with associated subendocardial perfusion defects and myocardial edema. These were felt to be in the distributions of the left circumflex and left anterior descending arteries and likely due to vasospasm, so the patient was initiated on diltiazem. Allergy evaluated the patient and felt her symptoms represented KS. They recommended outpatient workup to identify an allergy trigger and discharge with an epinephrine pen. KS is a rare presentation of acute coronary syndrome in the setting of an allergic, hypersensitivity, or anaphylactic reaction. Clinicians must be aware of this phenomenon to be able to promptly diagnose and evaluate these patients as late diagnosis can lead to significant morbidity and mortality.
MON-757 Percutaneous Ethanol Ablation (PEA) Of Parathyroid Adenomas: A Single-Center Outcomes Study
Hewlett, Jennifer R, Wermers, Robert A. , Schmitz, John J. , Sfeir, Jad

Mayo Clinic

Journal of the Endocrine Society | October 23, 2025 | Volume: 9 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvaf149.499 Get It

Abstract Disclosure: J.R. Hewlett: None. J.G. Sfeir: None. R.A. Wermers: None. J.J. Schmitz: None. Percutaneous ethanol ablation (PEA) is a non-surgical technique used in the management of hyperparathyroidism (HPT) since the 1980s. Previously published cohorts are small and/or focused on patients with primary hyperparathyroidism (PHPT) in the setting of multiple endocrine neoplasia type 1 (MEN1). New randomized controlled trial data suggests similar response rates between parathyroidectomy and PEA (98.5% vs 91.1%) for uniglandular disease, and a previously published cohort of PEA in patients with MEN1 and recurrent multiglandular PHPT at our institution reported post-PEA normocalcemia in 74.5% of patients. This retrospective cohort study examined the treatment response to PEA in those with PHPT (including MEN1) and tertiary HPT (THPT) at a single institution between 1997-2023. Those with secondary hyperparathyroidism or eucalcemic PHPT were excluded. The primary outcome was a serum calcium ≤10.1 mg/dL at 3-6 months and secondary outcomes included number and volume of ethanol injections, time to recurrence of HPT, and complications of PEA. A total of 83 patients were included. Most were women (62.7%) and the median age at diagnosis of HPT was 40 years. The majority had PHPT (90.4%), and many (86.7%) had previously undergone surgery. The most common indications for PEA were risk for hypoparathyroidism with additional surgery (72.3%) poor surgical candidacy (16.9%), and patient preference (8.4%). The mean calcium was 10.7 mg/dL (95% CI 10.56-10.85) and the mean PTH was 164 pg/mL (95% CI 120.6-208.3) prior to PEA. The mean number of ethanol injections was 3.0 (95% CI 2.6 – 3.4) and the cumulative volume of ethanol was 1.2 mL (95% CI 1.0-1.4). At 3-6 months, 68.3% of treated patients had calcium ≤10.1 mg/dL with a mean value of 9.4 mg/dL (95% CI 9.1-9.6). Of those, 42% did not have recurrence at most recent follow-up. Of those with recurrence, a post-PEA calcium ≤10.1 mg/dL at 3-6 months was associated with a longer time to recurrence than those without (36.9 months versus 3.75 months; P=0.0009). There was no significant difference between the number of times (P=0.56) or the volume (P=0.41) of ethanol injected between those with calcium of ≤10.1 mg/dL at 3-6 months and those without. Hypocalcemia was observed in 8 (9.6%; transient in 75%), hypoparathyroidism in 3 (3.6%; transient in 66.7%), laryngeal nerve injury in 2 (2.4%; transient in 50%), and hoarseness in 9 (10.8%; transient in 100%) patients. This is the largest North American cohort of patients who received PEA for HPT and represents a broader review of HPT than previously published. Our rate of post-PEA eucalcemia is lower than previously reported, however this cohort was complex with a high proportion of multiglandular disease (80.7%), MEN1 (39.8%) and prior surgeries (mean 1.7 per person; 95% CI 1.5-1.9). PEA remains a safe and effective treatment for patients with recurrent HPT, especially those at high risk of post-surgical hypoparathyroidism. Presentation: Monday, July 14, 2025
Hip Pain In A Weightlifter
Lowell, Luke, Hodges, Blake, Janitz, Tyler, Nadwodny, Jeff, Schmitz, Tyler, Hodges, Blake, Pujalte, George G.A. , Schmitz, Tyler

Mayo Clinic

Medicine & Science in Sports & Exercise | September 16, 2025 | Volume: 57 | Issue: 10S | Pages: 289-289

10.1249/01.mss.0001157092.36976.ca Get It

Inpatient and Outpatient Radiology Report Access After the 21st Century Cures Act
Tariq, Amara , Schmitz, John J. , Varner, Jacob, Metcalfe, Allie M., Pollock, Jordan Riley , Sharma, Umesh, Tan, Nelly

Mayo Clinic

JAMA Network Open | August 27, 2025 | Volume: 8 | Issue: 8 | Pages: e2528683

10.1001/jamanetworkopen.2025.28683 | PMID 40864472 Get It

This cohort study examines trends in patient access of radiology imaging results after implementation of the 21st Century Cures Act in different clinical settings.
Quantification of Initial Symptom Relief Following Ultrasound-Guided Radiofrequency Ablation of Benign Thyroid Nodules
Atwell, Thomas D. , Schmitz, John J. , Ryder, Mabel , Roll, Rebecca J, Castro, M. Regina , Kassmeyer, Blake A., Kurup, A. Nicholas , Ryder, Mabel , Stan, Marius N.

Mayo Clinic

Ultrasound Quarterly | May 15, 2025 | Volume: 41 | Issue: 2 | Pages: No page available

10.1097/ruq.0000000000000716 | PMID 40369808 Get It

Abstract The use of radiofrequency ablation (RFA) of benign, symptomatic thyroid nodules is growing in clinical practice. Objective outcomes of symptom relief are needed to support the use of this treatment. Thus, a previously established thyroid nodule symptom scoring system was prospectively administered to patients prior to RFA of symptomatic thyroid nodules and then at 1, 3, 6, and 12 months following ablation. A total of 38 patients of mean age 57 years were treated with RFA between August 2022 and January 2024 and completed at least 1 follow-up survey. Five of these patients underwent simultaneous ablation of 2 thyroid nodules; the remainder had a single nodule treated. Mean modified symptom score prior to RFA was 3.5 (SD 1.6) with higher scores correlating with increasing baseline nodule volume (R = 0.46, P = 0.0038). Patient symptom scores decreased at the first 1-month survey (mean 1.2; SD 1.3) and 3-month survey (mean 0.9; SD 1.3) with durable response in those patients with more extended follow-up. In those patients with imaging follow-up, decreasing nodule size was shown to correlate with decreasing symptoms. The early results of this study show that RFA of benign, symptomatic thyroid nodules results in quantifiable symptom relief within 3 months of treatment. Such objective measures of symptom relief may be used to measure long-term durability of treatment.